Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
Support Care Cancer
; 28(12): 6119-6128, 2020 Dec.
Article
en En
| MEDLINE
| ID: mdl-32856211
ABSTRACT
Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Cuidados Paliativos
/
Erupciones por Medicamentos
/
Inhibidores de Puntos de Control Inmunológico
/
Neoplasias
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Guideline
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Support Care Cancer
Asunto de la revista:
NEOPLASIAS
/
SERVICOS DE SAUDE
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos